SCHEMBL13101489

SCHEMBL13101489

CN1CCNN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPK1 P28482 1/20 0.38
CTSK P43235 1/20 0.35
HPGD P15428 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
ESR2 Q92731 1/20 0.33
NR1H2 P55055 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
THRB P10828 1/20 0.32
RECQL P46063 1/20 0.32
EPHX1 P07099 1/20 0.32
CYP1A2 P05177 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
HTT P42858 1/20 0.31
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28306165 0.85 USP2 (0.46) USP2SMN1; SMN2MAPK1CTSKHPGD
SCHEMBL13101487 0.83 USP2 (0.50) USP2SMN1; SMN2MAPK1HPGDKDM4E
SCHEMBL2125387 0.80 USP2 (0.42) USP2SMN1; SMN2MAPK1CTSKHPGD
SCHEMBL13101494 0.80 USP2 (0.34) USP2SMN1; SMN2MAPK1CTSKHPGD
SCHEMBL4923319 0.79 HPGD (0.41) USP2SMN1; SMN2MAPK1CTSKHPGD
SCHEMBL13100991 0.77 USP2 (0.40) USP2SMN1; SMN2MAPK1CTSKHPGD
SCHEMBL1654758 0.77 HPGD (0.44) USP2SMN1; SMN2MAPK1CTSKHPGD
SCHEMBL13101492 0.76 USP2 (0.37) USP2SMN1; SMN2MAPK1HPGDNR1H2
SCHEMBL8874348 0.74 USP2 (0.60) USP2SMN1; SMN2HPGDMAPTTHRB
SCHEMBL82012 0.74 USP2 (0.60) USP2SMN1; SMN2HPGDMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530646-B2 Oxazolidinone derivative having 7-membered hetero ring RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2013-09-10 US disclosed
US-8530646-B2 Oxazolidinone derivative having 7-membered hetero ring RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2013-09-10 US disclosed
US-20100256355-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. 2010-10-07 US disclosed
US-20100256355-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. 2010-10-07 US disclosed
EP-2233484-A2 Oxazolidinone derivatives having a 7-membered heterocyclic ring Research Foundation Itsuu Laboratory (JP) 2010-09-29 EP disclosed
EP-2208729-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING Research Foundation Itsuu Laboratory (JP) 2010-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256355-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING NR0B2, NR0B1, NR2C2 USP2 3934/4885SMN1; SMN2 2032/4885MAPK1 3612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.